Bleeding, mortality, and antiplatelet therapy: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

Am Heart J. 2012 Jan;163(1):e1; author reply e3. doi: 10.1016/j.ahj.2011.10.004. Epub 2011 Nov 21.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Atherosclerosis / complications*
  • Female
  • Hemorrhage / mortality*
  • Humans
  • Male
  • Myocardial Ischemia / prevention & control*
  • Platelet Aggregation Inhibitors / adverse effects*
  • Thrombosis / drug therapy*
  • Ticlopidine / analogs & derivatives*

Substances

  • Platelet Aggregation Inhibitors
  • Ticlopidine